Cover Image

Anti-Obesity Drugs

Abstract

This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. The report profiles 59 companies including many key and niche players such as Arena Pharmaceuticals, Inc., AstraZeneca Plc., F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Orexigen Therapeutics, Inc., and VIVUS, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW

  • Market Yet to Unlock Potential
  • Obesity: An Unmet Medical Need
  • Obesity - A Global Epidemic
    • Table 1: Leading Countries by Percentage of Obese Population (2010) (includes corresponding Graph/Chart)
    • Table 2: Obesity Rates (%) in OECD Countries (includes corresponding Graph/Chart)
    • Table 3: Obese and Overweight & Obese Population in the World (2010): Percentage Share Breakdown by Region for US, European Union, and Rest of World (includes corresponding Graph/Chart)
    • Table 4: Abdominal Obesity Prevalence (%) by Region and Sex (includes corresponding Graph/Chart)
  • Trends and Issues
  • Rising Demand for Obesity Therapeutics
  • Growing Emphasis on Metabolism
  • Barriers to Development of Effective Drugs
  • New Research Aids in Discovery of Novel Drugs
  • Growing Problem of Obesity in Asia Particularly China
  • Online Drug Stores Boost Sales

3. COMPETITION

  • Roche Leads the Race
  • Withdrawal of High-Revenue Generating Drugs Affects Competition Metrics
    • Table 5: Leading Brands in the Global Anti-obesity Drugs Market (2010): Percentage Share Breakdown of Revenues for Xenical/orlistat, Reductil/Meridia (sibutramine), Alli, and Others (includes corresponding Graph/Chart)
  • Competition Grows with Pipeline Drugs
  • Current Anti-Obesity Drugs in Pipeline: 2011

4. OBESITY - AN INTRODUCTION

  • Diagnosis of Obesity
  • BMI Calculation and Classification
  • Waist Circumference and BMI
  • Causes of Obesity
  • Unhealthy Eating Habits
  • Environmental and Genetic Factors
  • Sedentary Lifestyle
  • Alcohol Intake
  • Childhood Obesity
  • Psychological Factors
  • Pregnancy
  • Hormonal Disorders
  • Drugs
  • Aging
  • Risks Associated with Obesity

5. OBESITY TREATMENT

  • Dietary Therapy
  • Exercise Therapy
  • Behavior Therapy
  • Pharmacotherapy
  • Weight Loss Surgery
  • Invasive Vis-a-vis Non-invasive Procedures
  • A Brief Review of Select Invasive Procedures
    • Bariatric Surgery
    • Laparoscopic Adjustable Gastric Banding
    • Vertical Banded Gastroplasty (VBG)
    • Roux-en-Y Gastric Bypass Procedure (RYGB)
    • Lap-Band Procedure
    • Gastric Band Procedure
    • Gastric Bypass Procedure
    • Doudenal Switch
  • Prescription Drugs Vis-a-vis Non-Prescription Drugs
    • Table 6: Obesity Treatment Options and Corresponding Success Rate

6. ANTI-OBESITY DRUGS - AN INSIGHT

  • Introduction
  • Mechanism of Action
  • Review of Available Drugs
  • Phentermine
  • Sibutramine
  • Orlistat
    • Anti-obesity Drugs, Brands and Mechanism of Action
    • Table 7: Global Anti-obesity Prescription Drugs Market (2010): Percentage Share Breakdown of Prescriptions by Physician Practices - Primary Care Physicians (PCP), Internal Medicine, Obstetrics/ Gynecology, Endocrinology/Diabetes, Psychiatry/ Neurology, Cardiology and Others (includes corresponding Graph/Chart)
  • Review of Select Drugs Awaiting approval / Under Trials

7. PRODUCT APPROVALS/LAUNCHES

  • FDA Expert Panel Recommends Approval of Orexigen's Contrave
  • Orexigen Receives FDA Approval for Anti-Obesity Drug
  • European Commission Authorizes Sale of Orlistat without Prescription in the UK
  • Sanofi-Aventis Receives Swiss Approval for Acomplia
  • Zydus Cadila Introduces Slimona
  • Torrent Introduces Rimoslim
  • Gencor Introduces Slimaluma
  • Orexigen Develops Excalia
  • Scripps Research Institute Develops Vaccine for Obesity
  • Sanofi-Aventis Receives Approval to Market Obesity Drug in EU
  • Sanofi-Aventis Rolls Out Acomplia
  • Sanofi Secures Approval for Acomplia in the UK
  • Novo Nordisk to Develop Anti-obesity Drug
  • Sanofi-Aventis Receives Approval to Market Acomplia in Mexico
  • Ind-Swift Introduces Sibuslim-10
  • Wellnx Launches NV
  • Iron-Tek Introduces Appetite Suppressant
  • Yamanouchi and Keio University Discover Target Molecule for Developing Anti-obesity Drug

8. RECENT INDUSTRY ACTIVITY

  • Takeda Enters into Partnership with Florida Hospital and SBMRI
  • DCGI Bans Sale of R-Sibutramine and Sibutramine
  • Abbot Withdraws Meridia
  • Takeda and Amylin Halt Clinical Studies of Pramlintide/ Metreleptin Combination Therapy
  • Isis Includes ISIS-FGFR4Rx into Drug Development Pipeline
  • Arrowhead Establishes Ablaris Therapeutics
  • Orexigen Enters into Partnership with Takeda
  • Ventana and GTMC Enter into Distribution Agreement
  • Taisho and Glaxo Group Enter into an Agreement
  • PROLOR Inks Agreement with YRDCL
  • Aegis Enters into Joint Commercialization Agreement with Albany Medical College
  • Wyeth Pharmaceuticals Acquires Thiakis

9. CORPORATE INITIATIVES IN THE RECENT PAST - A PERSPECTIVE BUILDER

  • Pfizer Halts CP-945, 598 Development
  • Shionogi to Acquire Sciele Pharma
  • Anthill Inks Agreement with Zafgen
  • EMEA Suspends Acomplia
  • GlaxoSmithKline to Sell Alli as OTC Drug
  • Sanofi-Aventis to Market Acomplia in UK
  • Orexigen Receives 4th US Patent for Contrave
  • BELLUS Health to Acquire Innodia
  • Ore Secures License to Develop Romazarit
  • GlaxoSmithKline Receives FDA Approval for Orlistat
  • Pfizer Receives Approval for Slentrol
  • GlaxoSmithKline Secures Licensing Rights of Orlistat
  • Pfizer Collaborates with Bristol-Myers Squibb
  • Takeda Collaborates with LG Life Sciences
  • Takeda to Acquire Paradigm
  • Sanofi-Aventis Secures Reimbursement Status for Acomplia
  • AstraZeneca Inks Agreement with Palatin Technologies
  • Switzerland Includes Acomplia in Reimbursement List
  • Allergan Pockets EndoArt
  • Sanofi-Aventis Receives Approval for Acomplia in Brazil
  • Biocon Inks MoU with Neopharma
  • Aurigene Partners with Forest Laboratories
  • Genaera Initiates First Human Trial of Trodusquemine
  • Neurogen Completes First Trial of NGD-4715
  • Alizyme Secures USFDA Approval for Cetilistat Trials
  • GW Pharma to Start Human Trials of New Anti Obesity Drug
  • Epix Completes Phase Ib Trial of PRX-07034
  • 7TM Pharma Starts Phase I/II Trial of TM30339
  • Pfizer Licenses Obesity Compounds from Bayer Pharmaceuticals
  • Merck Terminates Collaboration with Nastech
  • Sanofi-Aventis to Receive Rights for Rimonabant
  • UMN Pharma Inks Agreement with Crucell and DSM Biologics
  • 7TM Pharma Pockets CareX SA
  • BioLineRx Inks Licensing Agreement with Yissum
  • Arena Starts Phase III Clinical Trials of Lorcaserin
  • Drug Induced Serotonin Could Promote Weight Loss
  • Takeda Initiates Phase II Clinical Trials of ALT-962
  • Glenmark to Commence Phase I Trial of New Anti-Obesity Drug
  • Amylin-Leptin Integrated Therapy to Treat Obesity
  • Vivus Completes Phase II Trial of Qnexa
  • VERNALIS Starts Phase I trial for Obesity
  • 7TM Pharma Completes Phase I/ II Clinical Trials of TM30338

10. FOCUS ON SELECT PLAYERS

  • Arena Pharmaceuticals, Inc. (US)
  • AstraZeneca Plc (UK)
  • F. HOFFMANN-LA ROCHE LTD. (Switzerland)
  • GlaxoSmithKline Plc (UK)
  • Orexigen Therapeutics, Inc. (US)
  • VIVUS, Inc. (US)

11. GLOBAL MARKET PERSPECTIVE

  • Table 8: World Recent Past, Current & Future Market Analysis for Anti-Obesity Drugs by Geographic Region - US, Europe and Rest of World Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart)
  • Table 9: World Historic Review for Anti-Obesity Drugs by Geographic Region - US, Europe and Rest of World Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart)
  • Table 10: World 15-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2010 and 2017 (includes corresponding Graph/Chart)

12. THE UNITED STATES

  • A. Market Analysis
    • Market Overview
    • Table 11: Leading Product Segments in the US Weight Loss Market (2010): Percent Share Breakdown of Revenues for Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods, Artificial Sweeteners, Weight Loss Centers, Medically Supervised Programs, Meal Replacements & Appetite Suppressants, Prescription Drugs, Low Calorie Diet Programs and Others (includes corresponding Graph/Chart)
      • Obesity Catching Them Young
      • Key Statistics
    • Table 12: Obesity-Affected Population in the US (2010): Percentage Share Breakdown by Age Group (includes corresponding Graph/Chart)
    • Table 13: Proportion (%) of Obesity in the US Overweight Population by Age Group (includes corresponding Graph/Chart)
    • Table 14: Obesity and Overweight Prevalence in US Adults (2010) (includes corresponding Graph/Chart)
    • Table 15: Obesity Prevalence in US Adults by Type of Obesity (2010) (includes corresponding Graph/Chart)
      • State-wise Stats
    • Table 16: Top 20 US States by Obesity Rate (%) (2010) (includes corresponding Graph/Chart)
    • Table 17: US Obesity Prevalence Estimates and Forecasts (2006-2020) (includes corresponding Graph/Chart)
    • Reimbursement Scenario
    • Regulatory Environment
      • Insufficient Regulatory and Enforcement Laws
    • Obesity and Related Ailments: Burden on Societal and Economic Cost
    • Competition
    • Product Approval/Launches
    • Strategic Corporate Developments
    • Review of Major Players
  • B. Market Analytics
    • Table 18: US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 19: US Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13. EUROPE

  • A. Market Analysis
    • Market Overview
    • Obese Population in Europe
    • Table 20: Obese and Overweight & Obese Population in the European Union (2010): Percentage Share Breakdown by Age Group (includes corresponding Graph/Chart)
    • Table 21: Select EU Member Countries Ranked by Obesity Rates (2010) (includes corresponding Graph/Chart)
    • Table 22: Obesity Prevalence Rates (%) Among Adults by Gender (2010) (includes corresponding Graph/Chart)
      • Childhood Obesity Rates in EU
    • Focus on Select Players
  • B. Market Analytics
    • Table 23: European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 24: European Historic Review for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 25: European 15-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2003, 2010 and 2017 (includes corresponding Graph/Chart)

13a. FRANCE

  • A. Market Analysis
    • Market Overview
      • Changing Lifestyle Alter Health Profile
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 26: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 27: French Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13b. GERMANY

  • Market Analysis
    • Table 28: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 29: German Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13c. ITALY

  • Market Analysis
    • Table 30: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 31: Italian Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13d. THE UNITED KINGDOM

  • A. Market Analysis
    • Market Overview
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 32: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 33: UK Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13e. REST OF EUROPE

  • A. Market Analysis
    • Review of Select Markets
      • Spain
      • Belgium
      • The Netherlands
      • Finland
      • Sweden
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 34: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 35: Rest of Europe Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14. REST OF WORLD

  • A. Market Analysis
    • Brief Review of Select Regions
      • Asia-Pacific
      • Australia
    • Table 36: Prevalence Rate (%) of overweight/ obese Students in Australia (includes corresponding Graph/Chart)
      • China
      • India
      • Drugs Under Development by Indian Companies
      • Japan
      • Takeda Pharmaceutical Company Limited - A Key Player
      • Korea
      • Use of Diet Pills Lack Proper Monitoring
      • New Zealand
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 37: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 38: Rest of World Historic Review for Anti- Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Show More
Pricing
Get Notified
Email me when related reports are published